A pilot study on the impact of Hydroxiram D supplementation on nutritional status and sarcopenia-related parameters

Sarcopenia is a frequent and prognostically relevant complication of chronic liver disease. The SARCIRAM pilot trial investigated the effect of Hydroxiram D, a formulation of branched-chain amino acids (BCAAs), β-hydroxy-β-methylbutyrate (HMB), and vitamin D, on nutritional status and sarcopenia-related parameters in patients with compensated cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD). In this single-center, randomized pilot study, adults with compensated MASLD-related cirrhosis (Child-Pugh A) received Hydroxiram D plus standard care or standard care alone for 6 months. The primary outcome was phase angle (PA), while secondary outcomes were appendicular skeletal muscle mass (ASMM)/height², handgrip strength (HGS), and 4-meter walk test (4-mWT). Between-group comparisons used baseline-adjusted models. Post-hoc simulation analyses were used exploratorily to inform the design of future studies. Thirty-two patients were analyzed. After 6 months, the adjusted change in PA was significantly more favorable in the treated group versus controls (+ 0.36° vs. - 0.45°, p = 0.046). Between-group differences in muscle mass, HGS, and gait speed were not statistically significant, although effect estimates directionally favoured the intervention. No treatment-related adverse events were observed. Six months of Hydroxiram D was associated with a more favorable change in PA in patients with compensated MASLD-related cirrhosis, with favorable trends in muscle parameters. These hypothesis-generating findings warrant confirmation in larger, prospectively registered, double-blind trials to confirm efficacy and long-term outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Physiology and Biochemistry
Published
2026-11-12
DOI
https://doi.org/10.1007/s13105-026-01253-4
Primary Topic
Nutrition and Health in Aging
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A pilot study on the impact of Hydroxiram D supplementation on nutritional status and sarcopenia-related parameters

Paolo Gallo, Francesca Terracciani, Andrea Falcomatà, Umberto Vespasiani‐Gentilucci et al.
Journal of Physiology and Biochemistry
Nutrition and Health in Aging
article

A pilot study on the impact of Hydroxiram D supplementation on nutritional status and sarcopenia-related parameters

Paolo Gallo, Francesca Terracciani, Andrea Falcomatà, Umberto Vespasiani‐Gentilucci, Giorgio Reggiardo, Simone Di Cola, Antonio Picardi, Raffaele AntonelliIncalzi, Antonio De Vincentis, Valentina Flagiello, Dafne Marcelli, Lucrezia Santoro
article en

Abstract

Sarcopenia is a frequent and prognostically relevant complication of chronic liver disease. The SARCIRAM pilot trial investigated the effect of Hydroxiram D, a formulation of branched-chain amino acids (BCAAs), β-hydroxy-β-methylbutyrate (HMB), and vitamin D, on nutritional status and sarcopenia-related parameters in patients with compensated cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD). In this single-center, randomized pilot study, adults with compensated MASLD-related cirrhosis (Child-Pugh A) received Hydroxiram D plus standard care or standard care alone for 6 months. The primary outcome was phase angle (PA), while secondary outcomes were appendicular skeletal muscle mass (ASMM)/height², handgrip strength (HGS), and 4-meter walk test (4-mWT). Between-group comparisons used baseline-adjusted models. Post-hoc simulation analyses were used exploratorily to inform the design of future studies. Thirty-two patients were analyzed. After 6 months, the adjusted change in PA was significantly more favorable in the treated group versus controls (+ 0.36° vs. - 0.45°, p = 0.046). Between-group differences in muscle mass, HGS, and gait speed were not statistically significant, although effect estimates directionally favoured the intervention. No treatment-related adverse events were observed. Six months of Hydroxiram D was associated with a more favorable change in PA in patients with compensated MASLD-related cirrhosis, with favorable trends in muscle parameters. These hypothesis-generating findings warrant confirmation in larger, prospectively registered, double-blind trials to confirm efficacy and long-term outcomes.

Journal of Physiology and BiochemistryVol. 82(1)
Università Campus Bio-Medico (IT), Karolinska Institutet (SE), Consorzio per Valutazioni Biologiche e Farmacologiche (IT), Campus Bio Medico University Hospital (IT), Sapienza University of Rome (IT)
Karolinska Institutet
Good health and well-being
Nutrition and Health in Aging
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon